Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?
Appreciation of the immune effects of targeted agents has grown, and efforts to combine these agents with immunotherapy are underway to enhance therapeutic responses. Multiple ongoing trials are examining this concept; however, nuances exist with regard to timing, sequence, and combinatorial strategies. Clin Cancer Res; 23(2); 327-9. ©2016 AACRSee related article by Deniger et al., p. 351.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexandria P
AP
Cogdill
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Peter A
PA
Prieto
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexandre
A
Reuben
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jwargo@mdanderson.org.|Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jennifer A
JA
Wargo
D064987:Cell- and Tissue-Based Therapy / Q000639:trends*; D018390:Gene Targeting / Q000639:trends*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*